# Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Source: https://onco.cc/trials/nct05588648/  
OnCo record `nct05588648` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Vactosertib in osteosarcoma, run by MedPacto, Inc., now recruiting.

## Summary

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma is a phase 1/2 interventional study registered as NCT05588648 by MedPacto, Inc., with 48 participants planned, started 2023-05-01 and due to reach its primary completion in 2025-09. Interventions recorded: Vactosertib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05588648
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
- Sponsor: MedPacto, Inc.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT05588648: https://clinicaltrials.gov/study/NCT05588648

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [Vactosertib](https://onco.cc/drugs/vactosertib/)

---
JSON: https://onco.cc/api/v1/entities/nct05588648.json